Omeros Corporation (NASDAQ: OMER) today announced positive results from a Phase 2a clinical trial of OMS824, the company's phosphodiesterase 10 (PDE10) inhibitor, in which the drug was well tolerated and demonstrated comparable systemic ...
The US Food and Drug Administration (FDA) has cleared Omeros' investigational new drug application (IND) for OMS824 in Huntington's disease. OMS824 is developed to selectively inhibit phosphodiesterase 10 enzyme that is expressed in areas ...
Tags: Omeros'IND, Medicine
Omeros has filed an orphan drug application with the US FDA for OMS721, used to treat atypical hemolytic uremic syndrome (aHUS). OMS721 works by blocking the lectin pathway of the complement system while leaving intact the classical ...
Tags: Omeros, Orphan Drug, Medicine
Omeros has filed an investigational new drug application (IND) with the FDA for OMS824, the compound from its phosphodiesterase 10 (PDE10) program for schizophrenia and other cognitive disorders. OMS824 targets and inhibits an enzyme ...
Tags: new drug application, FDA, OMS824
Clinical-stage biopharmaceutical company Omeros Corporation said that it has discovered the proteins that activate the alternative pathway of the complement system as part of the company's mannan-binding lectin associated serine protease-2 ...
Tags: complement system, protease-2(MASP-2)program, pro-inflammatory protein